{"id":859,"date":"2025-01-23T13:19:30","date_gmt":"2025-01-23T13:19:30","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solutions&p=859"},"modified":"2025-09-26T09:09:52","modified_gmt":"2025-09-26T09:09:52","slug":"rheumatoid-arthritis","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/rheumatology\/rheumatoid-arthritis\/","title":{"rendered":"Rheumatoid Arthritis"},"content":{"rendered":"
\n \n
\n
\n
\n
\n

Biomarkers for rheumatoid arthritis<\/h2>\n \n\n <\/div>\n
\n

Rheumatoid arthritis is a chronic autoimmune joint disease caused by the body\u2019s immune system mistakenly attacking the body\u2019s own joints.<\/p>\n

Rheumatoid arthritis is characterized by inflammation at the lining of the joints, causing painful swelling which can eventually result in bone erosions and joint deformity, if left untreated.<\/p>\n

The disease can also cause damage to a wide variety of other body systems, including lungs, skin, eyes, heart, blood vessels and others.<\/p>\n

 <\/p>\n <\/div>\n <\/div>\n

\n \n Visit our rheumatology biomarker portfolio \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n\n
\n
\n
\n

The clinical need for biomarkers in rheumatoid arthritis<\/h2>\n

The need for biomarkers in rheumatoid arthritis<\/a>\u00a0today is two-fold. First, the diagnosis of rheumatoid arthritis remains a challenge because the signs and symptoms mimic those of many other diseases. Current biomarker techniques are imprecise and struggle to determine future prognosis of the patients.<\/p>\n

Despite great progress in the availability of new and efficacious drugs in the last decades, a significant proportion of patients fail to respond to treatment or lose treatment effect over time. Exploratory\u00a0biomarkers<\/a>\u00a0have the potential to greatly benefit patients, by aiding in the early diagnosis of disease and directing the most appropriate treatment at the right time. Furthermore, the use of\u00a0Nordic biomarkers to enrich or stratify patients likely to respond to a therapeutic drug in development trials may\u00a0reduce the trial length and sizerequired to determine\u00a0therapeutic efficacy.<\/p>\n <\/div>\n

\n

Why Nordic ProteinFingerPrint Technology\u2122 in rheumatoid arthritis<\/h2>\n

Rheumatoid arthritis is characterized by inflammation and tissue destruction in the joints.<\/p>\n

<\/p>\n

The tissues of the joint consist mainly of collagens. The collagens are remodeled as part of the normal homeostasis of the joint \u2013 that is, collagens are broken down and rebuilt as part of normal repair and maintenance of the tissue. In rheumatoid arthritis, the balance between degradation and formation of tissue is interrupted resulting in net degradation of the tissue. Nordic ProteinFingerPrint Technology\u2122<\/a> biomarkers measured\u00a0in our lab<\/a>\u00a0can quantify this tissue turnover directly in a serum sample.<\/p>\n

<\/p>\n

<\/p>\n

<\/div>\n

<\/p>\n

We have developed the RheumaTrace\u2122<\/a> biomarker portfolio for precise quantification of rheumatic diseases.<\/p>\n <\/div> \n <\/div>\n<\/section>\n\n\n

\n \n
\n
\n
\n
\n \n <\/div>\n
\n <\/div>\n \n \n
\n
\n\n \n Interested to learn more? Reach out! \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/article>\n <\/div>\n <\/section>\n\n\n
\n \n
\n
\n
\n
\n

RheumaTrace\u2122 panel: separation between healthy and diseased with pharmacodynamic biomarkers<\/h2>\n \n\n <\/div>\n
\n

RheumaTrace\u2122 is a next-generation biomarker panel developed to advance precision medicine in rheumatology. Built on over 30 years of research and more than 200 publications, it features seven biomarkers that capture key aspects of connective tissue degradation and immune activity. RheumaTrace\u2122 enables drug developers to track disease activity, predict treatment response, and identify target patient populations\u2014supporting smarter, faster decisions in clinical development.<\/p>\n

These biomarkers delve into the complexities of connective tissue degradation and immune cell dynamics, providing invaluable insights for researchers and drug developers. By pinpointing the disease pathway and determining the optimal dosage for positive outcomes, our panel is at the forefront of precision medicine in rheumatology.<\/p>\n <\/div>\n <\/div>\n

\n \n Learn more about RheumaTrace\u2122 \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n\n
<\/div>\n\n\n\n
\n

The Nordic ProteinFingerPrint Technology\u2122 in rheumatic disorders<\/h2>\n\n\n\n

Unsure about how our technology can benefit your clinical trial in rheumatic disorder? Watch this short video and get an understanding of the benefit you gain from our biomarkers .<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n